Cargando…

Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience

This study aimed to assess the effectiveness and safety of tocilizumab use for the treatment of active steroid-resistant Graves’ orbitopathy (GO). A retrospective longitudinal study was conducted by reviewing the medical records at a single center between November 2009 and December 2018. A total of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Moreiras, José V., Varela-Agra, María, Prada-Sánchez, M. Consuelo, Prada-Ramallal, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916878/ https://www.ncbi.nlm.nih.gov/pubmed/33670151 http://dx.doi.org/10.3390/jcm10040706

Ejemplares similares

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy
por: Russell, David J., et al.
Publicado: (2017)

A case of Tocilizumab-induced thrombocytopenia in steroid-resistant Graves orbitopathy
por: Cuculescu, Victoria, et al.
Publicado: (2023)

Long‐term outcomes in corticosteroid‐refractory Graves' orbitopathy treated with tocilizumab
por: Moi, Laura, et al.
Publicado: (2021)

Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients
por: Sánchez-Bilbao, Lara, et al.
Publicado: (2020)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study
por: Boutzios, Georgios, et al.
Publicado: (2023)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review
por: Prada-Ramallal, Guillermo, et al.
Publicado: (2019)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
por: Ruiz-Antorán, Belén, et al.
Publicado: (2020)

Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves’ orbitopathy and analysis on who requires additional therapy
por: Tsirouki, Theodora, et al.
Publicado: (2016)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy
por: Dogan, Aysun Sanal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dnmk254h30jhubi64fv4vu4fqd